This encompasses China, Asian and Eurasian markets, Middle East & Africa, Latin America, Australia & New Zealand.

“Iskra is a highly accomplished leader with extensive international experience across multiple disciplines and a track record of improving patient access to our innovative and life-changing medicines. Her experience building partnerships will be invaluable in taking the fast-growing International region forward,” says Pascal Soriot, CEO, AstraZeneca.

Leon Wang is on extended leave

Iskra succeeds Leon Wang who is on extended leave from the company while under investigation in China.

Related article

AstraZeneca China President currently under investigation

Leon Wang, Executive Vice President International and AstraZeneca China President, is cooperating with an ongoing investigation by Chinese authorities.


Iskra Reic

Iskra Reic joined AstraZeneca in 2001 and has since held numerous leadership positions within the Company, including as Executive Vice-President (EVP) for Europe & Canada and, since 2021, as EVP, Vaccines & Immune Therapies. She has also held senior roles across Central & Eastern Europe, Eurasia, Middle East and Africa. Iskra has served on AstraZeneca’s Senior Executive Team since 2017.

As EVP, Vaccines & Immune Therapies, Iskra was responsible for both the early and late-stage development of the Unit’s pipeline and portfolio, including COVID-19 and RSV vaccines and monoclonal antibodies, strategic partnerships and acquisitions, medical affairs and commercial operations.

Iskra has a PhD and an MBA in Business and Leadership from the IEDC-Bled School of Management, Slovenia. She also holds a DMD from the Medical University of Zagreb. She is a member of the Board of Directors of myTomorrows, a global health technology company, and Steering Committee of the Partnership for Health System Sustainability and Resilience, a global collaboration dedicated to improving patient outcomes.

“It is a privilege to lead this broad, diverse and innovative region as we deliver the next wave of science and innovative medicines. I look forward to working with our partners, stakeholders and colleagues to improve the lives of millions of people around the world with our leading medicines and vaccines,” says Iskra Reic.